Clinical pharmacology and clinical pharmacy: a marriage of necessity
The relationship between clinical pharmacology and clinical pharmacy has been periodically discussed over the past 40 years. [1] [2] [3] [4] The goal of this commentary is not to rehash old arguments but rather to point out how acutely each profession needs the other in 2012 and beyond. Global economics, a demand for quality cost effective drug therapy, a pharmacological armamentarium of increasing complexity and new choices for the best and brightest students combine to drive clinical pharmacology and clinical pharmacy together.
This commentary was invited on the basis of a presentation at the American College of Clinical Pharmacology Annual Meeting in Chicago, Illinois, USA in September 2011. The presentation focused on the US situation, so I apologise in advance for any comments that might not pertain to the situation in the UK and Europe. However, I think that the situation that I will discuss very much pertains to the American and the UK/European situation.
The focus of this discussion is critical problems facing both professions that should drive them together at the present time. In the case of clinical pharmacology, the lack of a critical mass of practitioners to deliver clinical pharmacology's public health commitment may very well serve to weaken and ultimately destroy the profession. In the case of clinical pharmacy, the struggle to bring cutting edge science into clinical pharmacy practice commitment for providing expertise for the most complex drug therapies in a 'hands-on' manner. A quick check of the mission and vision statements of the two US clinical pharmacology organisations, ASCPT I would encourage you to read this excellent history of clinical pharmacology. The answer to 'What is clinical pharmacology?' is directly addressed by Sir Dollery, and it is (a) a laboratory discipline of pharmacokinetics, drug metabolism and pharmacogenomics, (b) a design and data analysis profession of experimental protocols, drug utilisation and pharmacovigilance and (c) a clinical profession of 'hands-on' patient care, clinical investigation of drug interactions and adverse effects, and consultancy as an expert in drug therapy. As Sir Dollery explains, this wide expanse of knowledge and expertise is both a strength and a weakness. As an example, the US Food and Drug Administration Office of Clinical Pharmacology consist of 150 clinical pharmacologists/pharmacists, and we continue to struggle with having the expertise to address new and emerging science and therapies.
So there is little question that clinical pharmacology has a public health The dramatic change that may not be well known to people outside of the pharmacy profession is the growth of the number of people educated at the doctorate PharmD level in the USA. In 1990, the American Association of Colleges of Pharmacy mandated that the PharmD would be the entry level degree, resulting in about 8000 PharmD graduates yearly in the USA at this time. Since more than 90% of pharmacy students enter pharmacy school in the USA with a bachelor's degree, the 8 year educational programme parallels physician training in the USA. On a global basis, the PharmD degree is now being offered in Africa, Asia, the Middle East, Europe and throughout North America presently, and there are many other entry points into clinical pharmacy, including masters degrees and specialised residencies or other training programmes.
This growth is reflected in the number of clinical pharmacists who are academically based, who have residency and fellowship training, and who offer sophisticated clinical services for patients. Many of these clinical pharmacists in the USA are members of the American College of Clinical Pharmacy, which now has over 12 000 members. In contrast, membership in the US clinical pharmacology organisations has been stagnant for at least a decade (figure 1). Clinical pharmacology organisations have all but closed their eyes to this development, despite their inability to mount any plan to meet their public health commitment. The American College of Clinical Pharmacology has about 100 PharmD members, and ASCPT does little better with about 300 PharmDs.
Why should clinical pharmacy embrace clinical pharmacology?
While clinical pharmacy includes clinical research and has a number of highly respected researchers, clinical pharmacology still represents the majority of drug development pharmacologists in the world. Information on new drugs, basic studies of drug-drug interactions and dosage adjustments required by renal or hepatic dysfunction are primarily generated during drug development by clinical pharmacologists. Solving complex patient drug problems requires cutting edge scientific knowledge, and increased opportunities exist for clinical pharmacists to collaborate with clinical pharmacologists to address these problems. The marriage of clinical pharmacy and clinical pharmacology keeps the science in patient oriented pharmacy services, and that is essential for delivering the highest quality services and for recruiting the best people to clinical pharmacy/pharmacology.
An A critical axiom of strategic planning for any profession or organisation is that if
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Clinical pharmacy and clinical pharmacology have many reasons to work together to further patient care related to drug therapy. you are not moving forward, you are in fact moving backwards. Clinical pharmacology and clinical pharmacy should carefully consider their current situation, and make this a marriage that society and patients everywhere will benefit from.
